These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11817988)

  • 1. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.
    Beutels P; Edmunds WJ; Antoñanzas F; De Wit GA; Evans D; Feilden R; Fendrick AM; Ginsberg GM; Glick HA; Mast E; Péchevis M; Van Doorslaer EK; van Hout BA;
    Pharmacoeconomics; 2002; 20(1):1-7. PubMed ID: 11817988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of hepatitis immunization for US college students.
    Jacobs RJ; Saab S; Meyerhoff AS
    J Am Coll Health; 2003 May; 51(6):227-36. PubMed ID: 14510025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).
    Beutels P
    Health Econ; 2001 Dec; 10(8):751-74. PubMed ID: 11747055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland].
    Zurn P; Danthine JP
    Soz Praventivmed; 1998; 43 Suppl 1():S61-4, S134-7. PubMed ID: 9833269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
    Harris A; Yong K; Kermode M
    Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
    Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
    JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools.
    Navas E; Salleras L; Gisbert R; Dominguez A; Bruguera M; Rodríguez G; Galí N; Prat A
    Vaccine; 2005 Mar; 23(17-18):2185-9. PubMed ID: 15755592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.
    Levaux HP; Schonfeld WH; Pellissier JM; Cassidy WM; Sheriff SK; Fitzsimon C
    Pediatrics; 2001 Aug; 108(2):317-25. PubMed ID: 11483794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two vaccination strategies against hepatitis A and B in patients with chronic hepatitis C.
    Díez Redondo MP; Almaraz A; Jiménez Rodríguez-Vila M; Santamaría A; de Castro J; Torrego JC; Caro-Patón A
    Rev Esp Enferm Dig; 2009 Apr; 101(4):265-74. PubMed ID: 19492902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.
    Holliday SM; Faulds D
    Pharmacoeconomics; 1994 Feb; 5(2):141-71. PubMed ID: 10146907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic evaluation of various hepatitis B vaccination strategies in children and adolescents].
    Szucs TD; Smala A; Berger K; Windorfer A
    Med Klin (Munich); 1998 Aug; 93(8):468-77. PubMed ID: 9747102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.
    Van Damme P; Kane M; Meheus A
    BMJ; 1997 Apr; 314(7086):1033-6. PubMed ID: 9112852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context.
    Sartori AM; de Soárez PC; Novaes HM; Amaku M; de Azevedo RS; Moreira RC; Pereira LM; Ximenes RA; Martelli CM
    Vaccine; 2012 Dec; 30(52):7489-97. PubMed ID: 23107593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinating Thai adolescents against hepatitis A: is it cost-effective?
    Soogarun S; Wiwanitkit V
    Southeast Asian J Trop Med Public Health; 2002; 33 Suppl 3():145-8. PubMed ID: 12971496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations of hepatitis A vaccination in middle-income countries.
    Suwantika AA; Yegenoglu S; Riewpaiboon A; Tu HA; Postma MJ
    Expert Rev Vaccines; 2013 Dec; 12(12):1479-94. PubMed ID: 24168129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.